Putri Annisa Kamila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Putri Annisa Kamila has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Daniele Andreini
Department of University Cardiology and Cardiac Imaging, IRCCS Ospedale Galeazzi Sant’Ambrogio , Milan
3 shared publications- Hyuk-Jae Chang
Division of Cardiology, Yonsei Cardiovascular Center, Yonsei University Health System, Seoul, South Korea
3 shared publications Ae-Young Her
Division of Cardiology, Department of Internal Medicine, Kangwon National University, College of Medicine, Kangwon National University School of Medicine , Chuncheon
2 shared publicationsAlessia Gimelli
Department of Imaging, Fondazione Toscana Gabriele Monasterio , Pisa
2 shared publications- Alexander van Rosendael
Department of Cardiology, Utrecht University Medical Center , Utrecht
2 shared publications Bin Lu
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital , Beijing
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
Sex based differences in association between plaque burden and ischemia—a CREDENCE trial substudy
Aims: Women with coronary artery disease (CAD) typically have less severe stenosis and lower plaque burden than men but have disproportionately high adverse cardiovascular event rates. This study evaluated sex-based differences in quantitative plaque burden and its association with ischaemia. Methods and results: A post hoc exploratory analysis of the CREDENCE trial included 612 symptomatic patients (184 women, 428 men) with suspected stable CAD who underwent CCTA and invasive coronary angiography with fractional flow reserve (FFR) measurements. Total, calcified, and total non-calcified plaque burden and volume were quantified. Ischaemia was defined as FFR ≤0.8. Women were older (66.5 ± 9.1 vs. 63.5 ± 10.3 years, P = 0.001) with a lower prevalence of smoking. They exhibited less high-risk plaque, shorter lesion length, and lower stenosis severity. Plaque burden and volume were significantly lower in women across all components (all P < 0.05), except for calcified plaque burden. A 5% increase in plaque burden was significantly associated with ischaemia in women for total plaque (OR = 1.28, 95% CI [1.12–1.46], P < 0.001), calcified plaque (OR = 1.31, 95% CI [1.10–1.57], P = 0.003), and total non-calcified plaque (OR = 1.33, 95% CI [1.05–1.67], P = 0.017). In men, only total and total non-calcified plaque burden were significant predictors of ischaemia. Significant sex interactions were observed for total (P = 0.015) and calcified plaque burden (P = 0.046), indicating differential effects in women and men, but not for diameter stenosis (P = 0.928). Conclusion: Despite having a lower overall plaque burden, women exhibit a stronger association between plaque burden and ischaemia than men. Further investigation in prospective studies is warranted to better understand potential sex-related differences in CAD.
- 11 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
Open AccessSex based differences in association between plaque burden and ischemia—a CREDENCE trial substudy
Aims: Women with coronary artery disease (CAD) typically have less severe stenosis and lower plaque burden than men but have disproportionately high adverse cardiovascular event rates. This study evaluated sex-based differences in quantitative plaque burden and its association with ischaemia. Methods and results: A post hoc exploratory analysis of the CREDENCE trial included 612 symptomatic patients (184 women, 428 men) with suspected stable CAD who underwent CCTA and invasive coronary angiography with fractional flow reserve (FFR) measurements. Total, calcified, and total non-calcified plaque burden and volume were quantified. Ischaemia was defined as FFR ≤0.8. Women were older (66.5 ± 9.1 vs. 63.5 ± 10.3 years, P = 0.001) with a lower prevalence of smoking. They exhibited less high-risk plaque, shorter lesion length, and lower stenosis severity. Plaque burden and volume were significantly lower in women across all components (all P < 0.05), except for calcified plaque burden. A 5% increase in plaque burden was significantly associated with ischaemia in women for total plaque (OR = 1.28, 95% CI [1.12–1.46], P < 0.001), calcified plaque (OR = 1.31, 95% CI [1.10–1.57], P = 0.003), and total non-calcified plaque (OR = 1.33, 95% CI [1.05–1.67], P = 0.017). In men, only total and total non-calcified plaque burden were significant predictors of ischaemia. Significant sex interactions were observed for total (P = 0.015) and calcified plaque burden (P = 0.046), indicating differential effects in women and men, but not for diameter stenosis (P = 0.928). Conclusion: Despite having a lower overall plaque burden, women exhibit a stronger association between plaque burden and ischaemia than men. Further investigation in prospective studies is warranted to better understand potential sex-related differences in CAD.
- Open Access
- 13 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (6) , 1192-1204
Artificial intelligence-guided quantitative coronary CT assessment to rule-in or rule-out myocardial ischaemia
Aims: To evaluate the ability of artificial intelligence-based quantitative CT (AI-QCT) parameters, diameter stenosis, percent atheroma volume (PAV) and average lumen area (ALA) to rule-in or rule-out ischaemia. Methods and results: This post-hoc, vessel-level analysis included patients with suspected coronary artery disease from the computed tomographic evaluation of atherosclerotic determinants of myocardial ischaemia (CREDENCE) (612 patients; 1727 vessels) and PACIFIC-1 (208 patients; 612 vessels) studies who underwent CCTA and invasive fractional flow reserve (FFR). In addition to diameter stenosis, PAV and ALA were evaluated as key predictors of ischaemia. We report abnormal FFR prevalence based on these variables and define rule-out (75% prevalence, ischaemia highly likely; further testing typically unnecessary), and intermediate risk (15–75%, consider additional functional assessment). PAV and ALA were dichotomized using median values derived from the CREDENCE cohort (14.7% and 3.9 mm2) and validated in PACIFIC-1. In CREDENCE, all vessels with 1–24% stenosis were ruled-out. Among vessels with 25–49% stenosis, 74% met rule-out criteria, while 26%, characterized by large PAV and small ALA, were intermediate risk. Within the proposed framework vessels with 50–69% stenosis were classified as intermediate risk. For 70–99% stenosis, 93% met rule-in criteria, except a small subset with small PAV and large ALA. In PACIFIC-1, 86% of vessels with 14.7%), and ALA (70% are reliably ruled-in. This practical approach enhances the diagnostic utility of CCTA and streamlines clinical decision-making.
- 13 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (6) , 1192-1204
Open AccessArtificial intelligence-guided quantitative coronary CT assessment to rule-in or rule-out myocardial ischaemia
Aims: To evaluate the ability of artificial intelligence-based quantitative CT (AI-QCT) parameters, diameter stenosis, percent atheroma volume (PAV) and average lumen area (ALA) to rule-in or rule-out ischaemia. Methods and results: This post-hoc, vessel-level analysis included patients with suspected coronary artery disease from the computed tomographic evaluation of atherosclerotic determinants of myocardial ischaemia (CREDENCE) (612 patients; 1727 vessels) and PACIFIC-1 (208 patients; 612 vessels) studies who underwent CCTA and invasive fractional flow reserve (FFR). In addition to diameter stenosis, PAV and ALA were evaluated as key predictors of ischaemia. We report abnormal FFR prevalence based on these variables and define rule-out (75% prevalence, ischaemia highly likely; further testing typically unnecessary), and intermediate risk (15–75%, consider additional functional assessment). PAV and ALA were dichotomized using median values derived from the CREDENCE cohort (14.7% and 3.9 mm2) and validated in PACIFIC-1. In CREDENCE, all vessels with 1–24% stenosis were ruled-out. Among vessels with 25–49% stenosis, 74% met rule-out criteria, while 26%, characterized by large PAV and small ALA, were intermediate risk. Within the proposed framework vessels with 50–69% stenosis were classified as intermediate risk. For 70–99% stenosis, 93% met rule-in criteria, except a small subset with small PAV and large ALA. In PACIFIC-1, 86% of vessels with 14.7%), and ALA (70% are reliably ruled-in. This practical approach enhances the diagnostic utility of CCTA and streamlines clinical decision-making.
- 31 July 2025
- Published by Brawijaya University in Heart Science Journal
- Vol. 6 (3) , 1-3
Redefining cardiovascular risk stratification: The evolving role of coronary CTA
Coronary computed tomography angiography (CCTA) has evolved far beyond its initial role as an anatomical imaging modality. Today, it serves as a versatile, multiparametric tool for cardiovascular risk assessment. This progress has been driven by advances in plaque characterization, non-invasive functional assessment, coronary inflammation imaging, and artificial intelligence (AI). CCTA enables clinicians not only to detect obstructive coronary artery disease but also to evaluate total plaque burden and high-risk plaque characteristics, such as low-attenuation components and positive remodeling. The addition of fractional flow reserve derived from CCTA (FFR-CT) offers myocardial ischemia assessment without the need for invasive testing. More recently, the perivascular fat attenuation index (FAI) has emerged as a promising marker of coronary inflammation, highlighting patients who may have residual inflammatory risk despite non-obstructive disease. AI-driven tools, including models like AI-QCTISCHEMIA, now allow for automated and accurate plaque analysis and ischemia prediction. The advent of photon-counting detector CT (PCD-CT) complements these advancements by improving spatial resolution and visualization of vulnerable plaque. These developments are reshaping the role of CCTA in clinical practice—from a diagnostic test to an integrated platform for individualized cardiovascular prevention and management. Keyword: Artificial Intelegence; Atherosclerosis; CCTA; Coronary Artery Disease.
- 31 July 2025
- Published by Brawijaya University in Heart Science Journal
- Vol. 6 (3) , 1-3
Redefining cardiovascular risk stratification: The evolving role of coronary CTA
Coronary computed tomography angiography (CCTA) has evolved far beyond its initial role as an anatomical imaging modality. Today, it serves as a versatile, multiparametric tool for cardiovascular risk assessment. This progress has been driven by advances in plaque characterization, non-invasive functional assessment, coronary inflammation imaging, and artificial intelligence (AI). CCTA enables clinicians not only to detect obstructive coronary artery disease but also to evaluate total plaque burden and high-risk plaque characteristics, such as low-attenuation components and positive remodeling. The addition of fractional flow reserve derived from CCTA (FFR-CT) offers myocardial ischemia assessment without the need for invasive testing. More recently, the perivascular fat attenuation index (FAI) has emerged as a promising marker of coronary inflammation, highlighting patients who may have residual inflammatory risk despite non-obstructive disease. AI-driven tools, including models like AI-QCTISCHEMIA, now allow for automated and accurate plaque analysis and ischemia prediction. The advent of photon-counting detector CT (PCD-CT) complements these advancements by improving spatial resolution and visualization of vulnerable plaque. These developments are reshaping the role of CCTA in clinical practice—from a diagnostic test to an integrated platform for individualized cardiovascular prevention and management. Keyword: Artificial Intelegence; Atherosclerosis; CCTA; Coronary Artery Disease.
- Open Access
- 14 January 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (3) , 1848-1860
The ADESTE Trial: A Phase 2 Study of Enibarcimab, a Monoclonal Antibody Targeting Adrenomedullin, in Acute Heart Failure
Aims: This study aimed to conduct a phase 2 proof-of-concept and safety study to evaluate the effect of ENIBARCIMAB (EN), a non-neutralizing humanized monoclonal antibody targeting the N-terminus of adrenomedullin (ADM), administered immediately after stabilization with standard of care (SoC) treatment, in patients hospitalized for acute heart failure (AHF). Methods and results: This prospective, open-label, controlled, interventional, multicenter, dose-escalation study was conducted at two cardiology sites in Indonesia. Patients were divided into two interventional groups sequentially receiving 0.5 mg/kg (SoC + EN 0.5 mg/kg, n = 10; first cohort) and 2 mg/kg (SoC + EN 2 mg/kg, n = 10; second cohort) of EN via 1-h intravenous (IV) infusion within 48 h after admission for AHF. The control group (n = 10) was treated with SoC therapy for AHF therapy. All patients were monitored continuously within 24 h post-infusion and subsequent daily until discharge. Treatment-related serious adverse events (SAEs) were recorded during hospitalization and up to 90 days after discharge. Both EN dosages were well-tolerated, and no significant safety issues were identified during hospitalization and up to 90 days of follow up. SAEs occurred in 10% of patients in each EN group but were deemed not related to treatment. No significant differences in the occurrence of SAEs were found between the groups. Five deaths occurred: three (30%) in the control group as compared with two deaths (20%) in the SoC + EN 2 mg/kg group. EN led to a significant increase in plasma bio-ADM levels within 24 h post-infusion, with the SoC + 2 mg/kg group showing the highest increase. Within 1 h from IV EN infusion, SoC + EN 2 mg/kg compared with 0.5 mg/kg, resulted in a significant percentage reduction in systolic, diastolic blood pressure, and mean arterial pressure. However, it did not result in severe hypotension and the need for drug discontinuation. Conclusions: In this pilot safety study of patients hospitalized for AHF, IV infusion of EN 0.5 and 2 mg/kg increased circulating plasma bio-ADM levels and was well-tolerated without treatment-related SAEs occurring during hospitalization and up to 90 days after discharge.
- 14 January 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (3) , 1848-1860
Open AccessThe ADESTE Trial: A Phase 2 Study of Enibarcimab, a Monoclonal Antibody Targeting Adrenomedullin, in Acute Heart Failure
Aims: This study aimed to conduct a phase 2 proof-of-concept and safety study to evaluate the effect of ENIBARCIMAB (EN), a non-neutralizing humanized monoclonal antibody targeting the N-terminus of adrenomedullin (ADM), administered immediately after stabilization with standard of care (SoC) treatment, in patients hospitalized for acute heart failure (AHF). Methods and results: This prospective, open-label, controlled, interventional, multicenter, dose-escalation study was conducted at two cardiology sites in Indonesia. Patients were divided into two interventional groups sequentially receiving 0.5 mg/kg (SoC + EN 0.5 mg/kg, n = 10; first cohort) and 2 mg/kg (SoC + EN 2 mg/kg, n = 10; second cohort) of EN via 1-h intravenous (IV) infusion within 48 h after admission for AHF. The control group (n = 10) was treated with SoC therapy for AHF therapy. All patients were monitored continuously within 24 h post-infusion and subsequent daily until discharge. Treatment-related serious adverse events (SAEs) were recorded during hospitalization and up to 90 days after discharge. Both EN dosages were well-tolerated, and no significant safety issues were identified during hospitalization and up to 90 days of follow up. SAEs occurred in 10% of patients in each EN group but were deemed not related to treatment. No significant differences in the occurrence of SAEs were found between the groups. Five deaths occurred: three (30%) in the control group as compared with two deaths (20%) in the SoC + EN 2 mg/kg group. EN led to a significant increase in plasma bio-ADM levels within 24 h post-infusion, with the SoC + 2 mg/kg group showing the highest increase. Within 1 h from IV EN infusion, SoC + EN 2 mg/kg compared with 0.5 mg/kg, resulted in a significant percentage reduction in systolic, diastolic blood pressure, and mean arterial pressure. However, it did not result in severe hypotension and the need for drug discontinuation. Conclusions: In this pilot safety study of patients hospitalized for AHF, IV infusion of EN 0.5 and 2 mg/kg increased circulating plasma bio-ADM levels and was well-tolerated without treatment-related SAEs occurring during hospitalization and up to 90 days after discharge.
- Open Access
- 21 February 2024
- Published by Elsevier in Advances in Medical Sciences
- Vol. 69 (1) , 81-89
Can non-invasive cardiac hemodynamics and fluid content system (NICaS) parameters predict Acute Heart Failure outcomes in Caucasian and Asian patients in the emergency department?
- 21 February 2024
- Published by Elsevier in Advances in Medical Sciences
- Vol. 69 (1) , 81-89
Open AccessCan non-invasive cardiac hemodynamics and fluid content system (NICaS) parameters predict Acute Heart Failure outcomes in Caucasian and Asian patients in the emergency department?
- Open Access
- 3 January 2024
- Published by Elsevier in European Journal of Radiology
- Vol. 171, 111282
Image quality assessment of coronary artery segments using ultra-high resolution dual source photon-counting detector computed tomography
- 3 January 2024
- Published by Elsevier in European Journal of Radiology
- Vol. 171, 111282
Open AccessImage quality assessment of coronary artery segments using ultra-high resolution dual source photon-counting detector computed tomography
- Open Access
- 24 October 2023
- Published by Association for Computing Machinery (ACM)
- p. 612-618
Comparative Analysis of Classification Features for ECG Signal Classification on Raspberry Pi Using Wearable Sensor Data
The classification of Electrocardiogram (ECG) signals plays a crucial role in monitoring and diagnosing cardiac conditions. With the advancements in wearable sensor technology, ECG signals can now be acquired conveniently in real-time using portable devices such as Raspberry Pi. However, the efficient extraction and selection of classification features from ECG signals remain a challenging task. In this study, we present a comparative analysis of classification features for automated ECG signal classification on Raspberry Pi. We evaluate and compare various feature extraction techniques, such as PQRS morphology, RR Interval, and wavelet. The performance of these features is assessed using a machine-learning algorithm random forest. To conduct the experiments, we use proven ECG signal data from MIT BIH arrhythmia, feature extraction techniques were applied to the preprocessed data to derive informative features for classification. The extracted features were used to train and test the machine-learning models. Furthermore, the classifier models were used to predict heartbeats types from wearable sensor data in real time and continuously. The results of our comparative analysis demonstrate the effectiveness and suitability of different feature extraction methods for ECG signal classification on the resource-constrained Raspberry Pi platform. We identify the most discriminative features and evaluate their impact on classification performance. Moreover, we explore the trade-offs between computational complexity and classification accuracy. We discuss the advantages and limitations of each feature extraction technique and provide insights into the feasibility of implementing real-time ECG signal classification systems on wearable devices. Overall, this study contributes to the field of ECG signal analysis by providing a comprehensive comparative analysis of classification features for ECG signal classification on the Raspberry Pi platform. The results and insights obtained from this research can guide the development of efficient and accurate wearable-based ECG monitoring systems for timely diagnosis and intervention in cardiac healthcare applications.
- 24 October 2023
- Published by Association for Computing Machinery (ACM)
- p. 612-618
Open AccessComparative Analysis of Classification Features for ECG Signal Classification on Raspberry Pi Using Wearable Sensor Data
The classification of Electrocardiogram (ECG) signals plays a crucial role in monitoring and diagnosing cardiac conditions. With the advancements in wearable sensor technology, ECG signals can now be acquired conveniently in real-time using portable devices such as Raspberry Pi. However, the efficient extraction and selection of classification features from ECG signals remain a challenging task. In this study, we present a comparative analysis of classification features for automated ECG signal classification on Raspberry Pi. We evaluate and compare various feature extraction techniques, such as PQRS morphology, RR Interval, and wavelet. The performance of these features is assessed using a machine-learning algorithm random forest. To conduct the experiments, we use proven ECG signal data from MIT BIH arrhythmia, feature extraction techniques were applied to the preprocessed data to derive informative features for classification. The extracted features were used to train and test the machine-learning models. Furthermore, the classifier models were used to predict heartbeats types from wearable sensor data in real time and continuously. The results of our comparative analysis demonstrate the effectiveness and suitability of different feature extraction methods for ECG signal classification on the resource-constrained Raspberry Pi platform. We identify the most discriminative features and evaluate their impact on classification performance. Moreover, we explore the trade-offs between computational complexity and classification accuracy. We discuss the advantages and limitations of each feature extraction technique and provide insights into the feasibility of implementing real-time ECG signal classification systems on wearable devices. Overall, this study contributes to the field of ECG signal analysis by providing a comprehensive comparative analysis of classification features for ECG signal classification on the Raspberry Pi platform. The results and insights obtained from this research can guide the development of efficient and accurate wearable-based ECG monitoring systems for timely diagnosis and intervention in cardiac healthcare applications.
- Open Access
- 24 October 2023
- Published by Association for Computing Machinery (ACM)
- p. 167-172
Comparison of Several Wavelet Transform Techniques for Inferring ECG Signal Classification
Cardiovascular diseases (CDVs) remain a leading cause of death worldwide. Thus, the disease needs to be detected as early as possible. One of the solutions is using an automated ECG Signal prediction using machine learning or deep learning. Among the many techniques in automated ECG signal analysis, wavelet transform has been highlighted due to its effectiveness in denoising and feature extraction. Then, a Convolutional Neural Network (CNN) is performed to predict the heartbeat. In the group of many techniques in wavelet transform, it is necessary to find out which is better in heartbeat prediction not only to be trained and tested with a secondary dataset but also with a primary or real dataset of ECG signal. In this paper, we compare the wavelet transform techniques, such as Continuous Wavelet Transform (CWT), Discrete Wavelet Transform (DWT), and Stationary Wavelet Transform (SWT), and also do inferencing. Those techniques were trained and tested by MIT-BIH arrhythmia database. As a result, the highest test accuracy is achieved by CWT with 0.9908 accuracy. Then, by testing it with a 30-minute recording of the ECG signal, the shortest time in inferencing is achieved by DWT in 12.92 seconds. It also used the lowest memory with 109.98 MB and SWT achieved the lowest CPU usage in inferencing with 26.34%.
- 24 October 2023
- Published by Association for Computing Machinery (ACM)
- p. 167-172
Open AccessComparison of Several Wavelet Transform Techniques for Inferring ECG Signal Classification
Cardiovascular diseases (CDVs) remain a leading cause of death worldwide. Thus, the disease needs to be detected as early as possible. One of the solutions is using an automated ECG Signal prediction using machine learning or deep learning. Among the many techniques in automated ECG signal analysis, wavelet transform has been highlighted due to its effectiveness in denoising and feature extraction. Then, a Convolutional Neural Network (CNN) is performed to predict the heartbeat. In the group of many techniques in wavelet transform, it is necessary to find out which is better in heartbeat prediction not only to be trained and tested with a secondary dataset but also with a primary or real dataset of ECG signal. In this paper, we compare the wavelet transform techniques, such as Continuous Wavelet Transform (CWT), Discrete Wavelet Transform (DWT), and Stationary Wavelet Transform (SWT), and also do inferencing. Those techniques were trained and tested by MIT-BIH arrhythmia database. As a result, the highest test accuracy is achieved by CWT with 0.9908 accuracy. Then, by testing it with a 30-minute recording of the ECG signal, the shortest time in inferencing is achieved by DWT in 12.92 seconds. It also used the lowest memory with 109.98 MB and SWT achieved the lowest CPU usage in inferencing with 26.34%.